Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

Background: EGFR mutations are present in approximately 15–50% of non-small cell lung cancer (NSCLC), which are predictive of anti-EGFR therapies. At variance, NSCLC patients harboring KRAS mutations are resistant to those anti-EGFR approaches. Afatinib and allitinib are second-generation pan-EGFR d...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva-Oliveira, Renato José, Gomes, Izabela Natalia Faria, da Silva, Luciane Sussuchi, Lengert, André van Helvoort, Laus, Ana Carolina, Melendez, Matias Eliseo, Munari, Carla Carolina, Cury, Fernanda de Paula, Longato, Giovanna Barbarini, Reis, Rui Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317664/
https://www.ncbi.nlm.nih.gov/pubmed/35887120
http://dx.doi.org/10.3390/ijms23147774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317664/
https://www.ncbi.nlm.nih.gov/pubmed/35887120
http://dx.doi.org/10.3390/ijms23147774

Ejemplares similares